

The 2nd International Workshop on Radiobiology of Molecular Radionuclide Therapy (IWRMR)

13th - 14th March 2023

Francis Crick Institute, London UK

Day 1 – Monday 13th March 2023

9.00 - 10.00	Registration with tea and coffee
Session 1 - Chairs: Samantha Terry, Bart Cornelissen	
10.00 - 10.10	Welcome <i>Samantha Terry, King's College London, UK</i>
10.10 - 11.10	Keynote 1: State-of-the-art MRT and where efforts best laid for impactful clinical success <i>Jonathan Wadsley, University of Sheffield, UK</i>
11.10 - 12.10	Promising efficacy of CAIX-targeted lutetium-177 radionuclide therapy combined with immune checkpoint inhibition <i>Simone Kleinendorst, Radboud University Medical Centre, Netherlands</i>
	p53 stabilization potentiates ¹⁷⁷ Lu-DOTATATE treatment in neuroblastoma <i>Hanna Berglund, Uppsala University, Sweden</i>
	Chemotherapeutic pre-treatment enhances [¹⁷⁷ Lu]Lu-DOTA-TATE therapy in cancer cells' <i>Jordan Cheng, King's College London, UK</i>
12.10 - 13.15	Lunch
Session 2 - Chairs: Julie Nonnekens, Mark Gaze	
13.15 - 14.15	MRT and vesicle signaling <i>Julie Constanzo, Montpellier Cancer Research Institute IRCM, France</i>
14.15 - 15.15	Characterization and role of dsDNA contained in extracellular vesicles released by irradiated cells <i>Yasmine Bouden, Université de Montpellier, France</i>
	The anti-tumour immune response induced by [¹⁷⁷ Lu]Lu-PSMA <i>Gemma Dias, University of Oxford, UK</i>
	Molecular targeted radiotherapy induces a systemic immune response in men with prostate cancer <i>Sapna Lunj, The University of Manchester, UK</i>
15.15 - 15.45	Poster Pitches - Chair: Jane Sosabowski
15.45 - 16.30	Tea and Coffee Break with Poster session 1
16.30 - 17.30	Networking session - Chair: Samantha Terry
17.30 - 19.30	Drinks Reception

Day 2 – Tuesday 14th March 2023

9.00 – 9.30	Tea & Coffee
	Session 1 – Chairs: Joelle Gaschet, Edward O'Neill
9.30 – 10.00	Targeting hypoxic WSB-1 biology as a radiosensitising approach in breast cancer <i>Isabel Pires, University of Hull, UK</i>
10.00 – 11.00	Audience-engaged discussion Chairs: Julie Nonnekens, Samantha Terry
11.00 - 11.20	Tea & Coffee Break
	Session 2 – Chairs: Mark Konijnenberg, Sarah Baatout
11.20 - 12.20	Keynote 2: How the tumour microenvironment might influence MRT success <i>Fran Balkwill, Queen Mary University of London, UK</i>
12.20 - 12.30	Industry talk: <i>Marco Ranzani, Artios, UK</i>
12.30 - 13.45	Lunch and Poster session 2
	Session 3 – Chairs: Tim Smith, Uta Eberlein
13.45 - 14.45	Cellular studies of ⁶⁷ Ga/ ¹⁷⁷ Lu-labeled nanoparticles for the theranostics of glioblastoma <i>Paula Raposinho, Technical University of Lisbon, Portugal</i>
	Challenges in radiation biology: from the radiation' nano-scopic pattern to biological effectiveness <i>Ana belchior, Technical University of Lisbon, Portugal</i>
	Absorbed dose-effect relationship in tumours and healthy organs for patients treated with ¹⁷⁷ Lu-DOTATATE <i>Emmanuel Deshayes, Montpellier Cancer Research Institute IRCM, France</i>
14.45 - 15.30	Tea & Coffee break with Networking
	Session 4 – Chairs: Mark Gaze, Jane Sosabowski
15.30 - 16.10	Clonogenic-based drug screens for lutetium-based combination therapy <i>Edward O'Neill, University of Oxford, UK</i>
	High-throughput screens identify DNA-PKcs inhibitors as radiosensitizers for peptide receptor radionuclide therapy <i>in vitro</i> and <i>in vivo</i> <i>Thom Reuvers, Erasmus University Medical Centre, Netherlands</i>
16.10 - 16.30	Closing statements - <i>Samantha Terry, King's College London, UK</i>

Sponsors. Thank you to Viewpoint Molecular Targeting for sponsoring our lunches for this workshop and MILabs for sponsoring our drinks reception.

